NASDAQ:DMK DMK Pharmaceuticals (DMK) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free DMK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.04▼$0.5852-Week Range N/AVolume24.16 million shsAverage Volume1.16 million shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesSocial Media Get DMK Pharmaceuticals alerts: Email Address Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About DMK Pharmaceuticals Stock (NASDAQ:DMK)DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.Read More Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. DMK Stock News HeadlinesApril 19, 2024 | msn.comAustralia jobs shrink slightly in March, but labor market remains tightApril 19, 2024 | uk.investing.comEarly Easter causes EU new car sales to drop 5.2% in March, says ACEAApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 8, 2024 | msn.comIndia to become 3rd largest economy if PM Modi returns to power: JP NaddaMarch 28, 2024 | msn.comBoE's Haskel says rate cuts should be 'a long way off', FT reportsMarch 22, 2024 | msn.comElectoral bonds: Who received biggest amount from ‘Lottery King’ Santiago Martin's firm?March 18, 2024 | msn.comJairam Ramesh takes ‘black money’ dig at BJP over electoral bonds dataMarch 18, 2024 | msn.comPharma companies that failed quality tests, raided by IT department feature on electoral bond listApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 18, 2024 | msn.comAt Rs 509cr, ‘Lottery King’ contributed 79% of DMK’s income from electoral bondsMarch 18, 2024 | msn.comElectoral Bonds: Lottery king Santiago Martin's Future Gaming, Megha Engineering among top donors for DMKMarch 17, 2024 | morningstar.comDMK Pharmaceuticals Corp DMKPQMarch 17, 2024 | msn.com'Somebody Came To Our Office, Handed Over Envelope': Nitish's JDU 'Not Aware' Of Electoral Bond Donors Who Gave ₹10 CroreMarch 17, 2024 | msn.comCongress alleges black money routed to BJP’s accounts through electoral bondsMarch 15, 2024 | msn.comLottery for all: Santiago may have bonded across the boardMarch 14, 2024 | msn.comNeither Adani Nor Ambani In Electoral Bonds List; 10 Biggest Donors To Political Parties Are ...March 14, 2024 | msn.comElectoral bonds bumper: ‘Lottery king’ Santiago Martin No. 1 bond buyerMarch 14, 2024 | msn.comSeveral biz groups bought bonds via multiple entitiesFebruary 25, 2024 | msn.comCongress' three-term Tamil Nadu MLA Vijayadharani joins BJPFebruary 23, 2024 | investing.comDMK Pharmaceuticals Corp (DMKPQ)February 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)February 13, 2024 | finance.yahoo.comDMK Pharmaceuticals Corporation (DMKPQ)February 8, 2024 | edition.cnn.comDMK Pharmaceuticals CorporationFebruary 8, 2024 | msn.comDMK Pharmaceuticals Faces Nasdaq Suspension and DelistingFebruary 6, 2024 | msn.comDMK Pharmaceuticals Expects Nasdaq Delisting Amid BankruptcyFebruary 6, 2024 | msn.comUK services and composite PMI rises in JanuaryFebruary 6, 2024 | msn.comDMK Pharmaceuticals Files for Chapter 11 BankruptcySee More Headlines Receive DMK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DMK Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DMK CUSIPN/A CIK887247 Webwww.dmkpharmaceuticals.com Phone858-997-2400FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-630.85% Pretax Margin-600.29% Return on EquityN/A Return on Assets-251.02% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.54 Sales & Book Value Annual Sales$3.62 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / BookN/AMiscellaneous Outstanding Shares10,102,000Free Float9,506,000Market Cap$2.34 million OptionableNo Data Beta1.11 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Seth Abraham Cohen (Age 61)Chief Financial Officer Mr. John W. Dorbin Jr. (Age 53)General Counsel Corporate Secretary Mr. Eddie Wabern Glover (Age 74)Chief Executive Officer of US Compounding Inc Key CompetitorsSonoma PharmaceuticalsNASDAQ:SNOACyclacel PharmaceuticalsNASDAQ:CYCCAltamira TherapeuticsNASDAQ:CYTONotable LabsNASDAQ:NTBLCNS PharmaceuticalsNASDAQ:CNSPView All Competitors DMK Stock Analysis - Frequently Asked Questions Should I buy or sell DMK Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DMK Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DMK shares. View DMK analyst ratings or view top-rated stocks. What is DMK Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12 month price objectives for DMK Pharmaceuticals' shares. Their DMK share price targets range from $1.50 to $1.50. On average, they predict the company's share price to reach $1.50 in the next twelve months. View analysts price targets for DMK or view top-rated stocks among Wall Street analysts. This page (NASDAQ:DMK) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DMK Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
